Immuno-PET imaging of VEGFR-2 expression in prostate cancer with
Positron emission tomography (PET)
prostate cancer
ramucirumab
vascular endothelial growth factor receptor 2 (VEGFR-2)
zirconium-89
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
07
2019
accepted:
06
08
2019
entrez:
11
10
2019
pubmed:
11
10
2019
medline:
11
10
2019
Statut:
epublish
Résumé
The detection and monitoring of prostate cancer (PrCa) malignancies using most of the conventional strategies is challenging. As an over-expressed biomarker of PrCa, the vascular endothelial growth factor receptor 2 (VEGFR-2) can be delineated by non-invasive imaging to address such issue. Herein, we report the positron emission tomography (PET) of VEGFR-2 expression in a PrCa mice models by composing a novel tracer, [
Types de publication
Journal Article
Langues
eng
Pagination
2037-2046Subventions
Organisme : NCI NIH HHS
ID : P30 CA014520
Pays : United States
Informations de copyright
AJCR Copyright © 2019.
Déclaration de conflit d'intérêts
None.
Références
Clin Cancer Res. 2004 May 15;10(10):3365-70
pubmed: 15161690
Amino Acids. 2010 Jun;39(1):11-27
pubmed: 19946787
Cancer J. 2013 Jan-Feb;19(1):90-8
pubmed: 23337762
Expert Opin Drug Deliv. 2014 Feb;11(2):175-85
pubmed: 24400729
Am J Clin Pathol. 2001 Jul;116(1):115-21
pubmed: 11447740
Clin Cancer Res. 2010 Jul 15;16(14):3548-61
pubmed: 20606037
Endocr Relat Cancer. 2015 Jun;22(3):R107-23
pubmed: 25870249
Asian J Androl. 2012 Sep;14(5):745-51
pubmed: 22705563
Prostate Cancer. 2013;2013:418340
pubmed: 24396604
Urology. 1999 Sep;54(3):567-72
pubmed: 10475375
Clin Cancer Res. 2014 Feb 1;20(3):617-30
pubmed: 24097861
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Phys Med. 2017 Nov;43:1-5
pubmed: 29195550
Expert Opin Biol Ther. 2013 Aug;13(8):1187-96
pubmed: 23803182
Methods. 2017 Nov 1;130:36-41
pubmed: 28711565
Invest Radiol. 2017 Jul;52(7):419-427
pubmed: 28257340
Invest Radiol. 2010 Oct;45(10):573-8
pubmed: 20808233
Am J Nucl Med Mol Imaging. 2011;1(1):65-75
pubmed: 23133797
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120
pubmed: 28821924
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):
pubmed: 29311132
J Labelled Comp Radiopharm. 2018 Jul;61(9):693-714
pubmed: 29537104
Cancer Res. 2002 Feb 1;62(3):854-9
pubmed: 11830543
Cancer Res. 2001 Mar 15;61(6):2736-43
pubmed: 11289156
Eur J Cancer. 2004 May;40(7):1066-72
pubmed: 15093584
Eur J Cancer. 2015 Sep;51(13):1714-24
pubmed: 26082390
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1372-1381
pubmed: 29450576
J Nucl Med. 2016 Feb;57(2):285-90
pubmed: 26541778
Clin Cancer Res. 2014 Feb 1;20(3):525-7
pubmed: 24284057
Mol Pharm. 2018 Apr 2;15(4):1627-1634
pubmed: 29537283
Korean J Radiol. 2013 Jan-Feb;14(1):30-7
pubmed: 23323028
Clin Cancer Res. 2014 Dec 1;20(23):5875-81
pubmed: 25281695
Drugs. 2013 Dec;73(18):2003-15
pubmed: 24277700